Summary. Hyperglycaemia in diabetes mellitus is responsible for the process of non-enzymatic glycosylation of different proteins. Since we did not find elevated glycated apolipoprotein B levels in diabetic patients, an altered glycated apolipoprotein B metabolism was suspected in diabetic patients. Experiments in normal rabbits showed that non-reductive (in vitro) glycated low density lipoprotein (gly-LDL) was cleared at a slower rate than control LDL and thus stayed longer in the circulation (vascular mean residence time: 10 vs 8 h, p < 0.001). The body mean residence time for gly-LDL was 22 h vs 17 h for control LDL. In diabetic animals the catabolic parameters of both LDL preparations changed towards a faster clearance, the effect being greatest for gly-LDL (total mean residence times of gly-LDL pre-diabetic: 19 h, diabetic: 16 h; control LDL pre-diabetic and diabetic: 14 h). The difference in clearance between glycated and control LDL was thus strongly reduced. Virtually no antibody complexed to gly-LDL could be measured. The results suggest an increased activity of the non-receptor mediated pathway in diabetes mellitus, possibly co-responsible for an increased atherosclerotic risk.
Diabetes mellitus is due to a defect in insulin production or response, with increased blood glucose concentration being the most striking consequence. One of the major complications of diabetes is atherosclerosis, which is also dependent on hyperlipidaemia.
One effect of hyperglycaemia is the increased nonenzymatic glycation of all kinds of proteins including apolipoproteins. The level of apolipoprotein B (apo B), the structure apoprotein of LDL, is known to be correlated to glyeated haemoglobin [1, 2] . Total and LDL-cholesterol are often [3] [4] [5] [6] but not always [7, 8] increased in diabetes, and a reduction in LDL-Cholesterol or apo-B is usually achieved upon intensified treatment [8] [9] [10] . Goldstein and Brown [11, 12] showed that modification of epsiIon-amino groups (lysine) of apo-B resulted in an inhibition of the binding and uptake by the apo-B/E or LDL receptor. Glycation of apo-B takes place on lysyl groups, shielding the LDL-receptor binding domain. It has been shown that in vitro glycation of LDL blocks the uptake and degradation by endothelial cells [13] , fibroblasts [14, 15] and hepatocytes [16] . A decreased in vivo catabolism of in vitro glycated LDL (gly-LDL) has been observed both in animals and man. This glycation was achieved mostly in the presence of cyanoborohydride [17, 18] , resulting in glucitollysine not present in vivo. A decreased catabolism of glycated apo-B (gly-apo B) would relatively exaggerate the percentage glycation of total apo-B which is already raised due to increased glucose levels. Surprisingly, in diabetes only a slight increase in glycated LDL [19, 20] or no increase at all of glycated apo-B [2] were reported. As glycated LDL seems to be catabolized at a slower rate than control LDL in non-diabetic subjects [17, 18, 21, 22] an increased turnover by the scavenger or nonreceptor-mediated pathway in diabetes may be operative.
To test this hypothesis we studied the removal of both control LDL-apo-B and glycated LDL-apo-B, prepared in the absence of cyanoborohydride in normal and alloxan-induced diabetic rabbits. Our observations are expressed in mean time parameters because of their great conceptual value.
Materials and methods

Animals
Twelve male New Zealand white (NZW) rabbits weighing 3 to 5 kg (mean weight 3.8 kg) were maintained on Purina Rabbit Chow Hope Farms 6345, Woerden, The Netherlands. Diabetes was induced by single intravascular inj ection of 70 mg/kg freshly prepared alloxan (A8128, Sigma, St Louis, Mo, USA) 30 mg/ml in 0.9 % NaC1 for 3-5 min. Local anaesthesia was applied. After injection the rabbits were provided with 10% glucose in their drinking water during the critical first 24 h. Five rabbits died, three of them within 24 h.
Labelled LDL was injected 11 or 14 days after alloxan treatment. Diabetes was assessed by measurement of blood glucose, glycated haemoglobin and glycated protein (Pierce columns (Rockford, Ill, USA), Bradford protein assay (Biorad, Veenendaal, The Netherlands).
Lipoprotein isolation and labelling
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Data analysis
Plasma decay curves of radioiodinated LDL tracers were analysed using the Enz-fit program from Elsevier [27] . The data were fitted to a least square double-exponential curve with proportional weighing. Mean residence times (MRT) of the whole body (MRTB), the central and the peripheral space (MRTc and MRTp) were calculated according to Veng-Pedersen [28] . The fractional catabolic rate according to Matthews [29] equals to 1/MR~Ic of Vcng-Pedersen [28] . Significance was tested by the paired Student's t-test. Correlations were calculated by linear regression analysis.
Fresh blood from ordinary rabbits was obtained from a local slaughter house. LDL was prepared by sequential ultracentrifugation according to Havel [23] in a L8-80 Beckman ultracentrifuge using a 60TI rotor and quick seal polyallomer tubes. After the first run at density 1.02 g/ml, 20 h and 150,000 x g the top fractions were removed by tube slicing. The bottom fractions were adjusted to density 1.063 g/ml, layered with a KBr solution of equal density and centrifuged as before. The LDL in the supernatant was collected and dialysed for 24 h against five changes of 5 volumes PBS (0.05 mol/1 phosphate, 0.15 tool/1NaC1, 1 retool/1EDTA, 0.02% NaN3 pH 7.4). Thereafter LDL was concentrated in a dialysis tube against Poly Ethylene Glycol 20,000 (Sigma, St Louis, Mo, USA).
Shortly before labelling LDL was dialysed against i mol/1 glycine pH 10.0. LDL from the same preparation was separated into two aliquots and labelled with either 131I or 125I according to the iodine monochloride method of McFarlane [24] . Typically 15-25 % of the label was recovered in the LDL fraction after removal of the free iodine through a Sephadex G-25 column (15 x i cm) equilibrated with PBS pH 7.4. Each labelled LDL was divided into two portions. From each labelled LDL preparation these portions were incubated for 48 h at 37~ with equal volumes of PBS with or without 100 retool/1D glucose. A 15 % glycation was achieved as determined by the measurement in radioactivity of the two fractions obtained after boronate affinity chromatography (Pierce, Rockford, Ill, USA) [2] whereas 3 % control LDL was glycated. The incubates were dialysed three times with 20 volumes 0.9 % NaC1. Glycated LDL was combined with control incubate of the alternate radioactive label, and sterile filtered through a 0.22 btm millipore filter. Each preparation was used for no more than three rabbits.
Experimental protocols
Rabbits were supplied with 200 mg/1 potassium iodine (KI) in their drinking water one day before injection with radioactivity and 100 rag/1 KI during the next 5 days. A mixture of labelled LDL and gly-LDL (5 gmol cholesterol or i mg protein) was injected into the left marginal ear vein at time t = 0 and blood samples obtained from the right ear vein at time t = 5, 30, 60, 90, 120 rain, 6, 12, 24, 48 and 72 h. EDTA plasma samples were counted in a double channel gamma-counter (Packard type 5210, Downers Grove, Ill, USA). Counts per rain (cpm) were corrected for background, channel carry over, and decay time. Apo-B related radioactivity was measured after precipitation with 50% isopropanol according to Yamada [25] and counted.
Antibody related radioactivity was tested for by incubating plasma with protein-A-sepharose CL-4B (Pharmacia, Uppsala, Sweden). Fifteen gg dry gel was allowed to swell in PBS and washed in the same buffer. The gel in 0.8 ml PBS was added to 100 gl plasma. After incubating for 20 min at room temperature the gel was centrifuged (3000 rev/min), washed twice with 8 ml PBS. After centrifugation the radioactivity in the pellet was measured. HbA1 was determined by boronate affinity chromatography as previously described [26] . Cholesterol, triglycerides and glucose were measured enzymatically by autoanalyzer using Boehringer Mannheim (Mannheim, FRG) reagents.
Results
The decay of plasma radioactivity or apo B radioactivity after isopropanol precipitation was essentially the same. The recovery of 12SI-apo B was 80 To ( + 7 To within each experiment) and of 13~I-apo B on average 6 % less within each sample (p < 0.0001). Parameters based on total plasma or apo B radioactivity revealed the same information although the magnitude of some parameters was slightly different (MRTc(apo B) = 1.23 MRTc(plasma) -3.3, MRTB = unchanged). The data presented are derived from apo B radioactivities after isopropanol precipitation.
In 12 non-diabetic animals the radioactivity associated with gly-LDL decreased at a lower rate than unmodified LDL (Fig. 1 a, Table 1 ). Using Student's t-test for paired measurements the mean residence times differed significantly (p < 0.001). The observed difference was only reflected by the slow removal-rate constant (p < 0.01) but not the fast removal-rate constant (NS; Table 1 , normal rabbits).
After a wash-out period of several weeks the animals were made diabetic by alloxan treatment. Their water intake and urine production were observed to be increased. No symptoms of dehydration were observed. The biochemical parameters indicating the diabetic state are presented in Table 2 . No insulin or other medication was given.
The catabolic parameters for LDL and gly-LDL in the animals made diabetic were different from the prediabetic state. No significant differences between glycated and non-glycated LDL in diabetic animals were present for either the residence time in the whole body (MRTB) or the central (MRTc) and peripheral compartment (MRTp) ( Table 1 ). The corresponding decay curves are shown in Figure i b.
To answer the question as to whether the clearance of LDL was reduced or the clearance of gly-LDL increased, the situation before and during diabetes was compared in the same animals. It appears that animals made diabetic show slightly decreased MRTc both for native LDL and gly-LDL (Table 1 ) and thus the particles were cleared at a faster rate from the circulation. The effect was more pronounced for gly-LDL (Figs. i c, d) . One of the six diabetic animals had a markedly increased cholesterol and trigtyceride level. The effect of the MRTc of LDL and gly-LDL in relation to the plasma cholesterol concentration of the six individual animals is shown in Figure 2 . The body 
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The shift in clearance between normal (D---m) and alloxan treated, diabetic (m---i) rabbits (n = 6) of control and glycated LDL is seen in c and ft. The symbols are means + SD mean residence time in rabbits made diabetic was only decreased for gly-LDL (Table 1) . In search of antibodies possibly responsible for a faster clearance of gly-LDL, samples were tested for protein-A bound radioactivity. No interfering IgG was present since less than i % radioactivity bound to protein A was found.
Discussion
The results presented show that glycated LDL was catabolized at a slower rate than control LDL in normal rabbits. In animals made diabetic, catabolism of gly-LDL increased to a greater extent than that of control LDL.
Physiologic modification such as glycation has been shown to inhibit the binding to the LDL receptor in vitro [13] [14] [15] [16] , and in vitro glycation interferes with the receptor mediated degradation of LDL [15, 17, 30] . In this study in 12 out of 12 NZW rabbits the removal of in vitro gly-LDL (15 % glycation) was less efficient than the removal of native LDL (3 %). The mean residence time (MRT) of gly-LDL was significantly higher than for control LDL. As the plasma decay curves were fitted according to double exponential equations, MRT's could be calculated for two compartments: a central space (MRTc) and a peripheral space (MRTp). The central space in this kinetic model is equivalent to the sampling space which in our experimental model, is the vascular space. The MRTc equals 1/fractional catabolic rate. The physiological meaning of the peripheral space in particular is speculative, but it can be associated with the tissue space. The residence time in both compartments was prolonged. The fast removal-rate constant, which serves as representative of the distribution rate between the intra-and extravascular space, did not differ significantly. The slow removal rate was significantly lower for gly-LDL. These observations are in accordance with the in vitro experiments, showing that gly-LDL is cleared at a slower rate if at all by the LDL receptor [14, 16] .
When establishing small differences in catabolism between preparations a possible difference in radioactive label might jeopardize the interpretation. Non-uniform radiolabelling has been described before [31] . We have therefore chosen a cross over of labels and glycation. The labels indeed behaved differently. Visual inspection of the decay curves showed slightly faster clearance of 131I as compared to 125I (not shown). Also, the efficiency of the isopropanol precipitation was different. The design of our study excluded this label bias at the expense of accuracy. Earlier reports of LDL kinetics in NZW-rabbits [15, 32, Differences in fast removal rate, slow removal rate and mean residence time (MRT) B, whole body; C, central space; R peripheral space in normal or diabetic rabbits, and between rabbits before and after alloxan-induced diabetes. Units in h 1 (rates) or h (MRT) ap < 0.01; Up < 0.001 Table 2 . Mean values (range) in six rabbits, before and after alloxan treatment 33] correspond well to our values based on plasma radioactivity, although the values calculated after isopropanol precipitation are slightly higher in our study than in other reports. The effect of glycation of apo-B on LDL kinetics seems to be unequivocal. In diabetic subj ects one would thus expect a strong increase in glycated apo B due to an accumulation of effects. An enhanced VLDL production is operative in diabetes mellitus [8, 34] , the glycating process is accelerated due to hyperglycaemia, and the uptake of gly-LDL is diminished. In contrast to this expectation some authors reported only slightly increased gly-LDL [19, 20] , while we did not find a significant elevation of glycated apo B levels in diabetic patients [2] . Therefore, we repeated the experiments in rabbits made diabetic by alloxan treatment, such that insulin treatment could be avoided. Interestingly, the differences between gly-LDL and native LDL catabolism were re- ( 9 ) and after ( 9 alloxan-induced diabetes duced as compared to the pre-diabetic state. No significant differences were seen for mean residence times. The reduction of the difference between LDL and gly-LDL was caused by a shift of all parameters towards an increased clearance. The shift was most pronounced f0r gly= LDL, The: increased fractional catabolic ra~e (Or de, creased MRT~) for (gtycated-) LDL in diabetic)vS:~Conir0! animals is present in all animals when baseline cholesterol and triglyceride concentrations remained constant. It looks like LDL and gly-LDL are transferred at a faster rate to the peripheral space. Nordestgaard and Zilversmit [33] showed increased arterial intima uptake of gly-LDL from diabetic rabbits as compared to native LDL. The decay curves of non-glycated and diabetic (glycated) LDL in normal rabbits did not however, differ from our observations. Their data gave no indication that arteries of diabetic rabbits are more permeable to LDL than in nondiabetic rabbits. Although not mentioned explicitly this was observed for both native LDL and gly-LDL. The peripheral residence time is only decreased for glycated LDL. The effects of MRTc and MRTF when normal rabbits were made diabetic are reflected in the MRTB which remained about the same for control LDL and decreased for gly-LDL.
The clearance of LDL and modified LDL is thought to be done mainly by the LDL receptor and the scavenger receptor respectively. Although an increased LDL receptor activity might have occurred in the diabetic state, an increased activity of the scavenger receptor is more likely. As gly-LDL is sometimes seen as a marker of scavenger receptor activity [17, 35] , it is tempting to think that the enhanced gly-LDL catabolism observed in the diabetic rabbits is caused by increased scavenger receptor activity because the increase in catabolism of gly-LDL is more pronounced. It can thus be postulated that atherogenesis in diabetic subjects with normal lipid concentrations is due to an increased catabolism of LDL and gly-LDL by the non-receptor mediated pathway. In support of this notion it has been observed that cholesterol levels in wellcontrolled diabetes are lower than those in healthy control subjects [7] . The observations of Kissebah et al. [6] are interesting in this respect. The authors reported a decreased fractional catabolic rate of LDL in uncontrolled diabetic subjects but an increased fractional catabolic rate in mildly diabetic, normolipaemic subjects as compared to control subjects. This would explain the observation that gly-LDL or glycated apo B is only marginally or not at all increased in human diabetic subjects. Several alternative explanations may be possible, such as the presence of antibodies against glycated lipoproteins. Our diabetic rabbits had been injected with gly-LDL before but plasma incubations with protein-A revealed no immunoglobulin bound radioactivity. Thus, if antibody-complexes once formed, are removed instantaneously this might explain some of our observations. The same may be true for the decreased central residence time of control LDL. However, some rabbits were, with a monthly interval, injected twice with LDL before they were alloxan treated, and no differences in kinetics between these rabbits and the normal rabbits injected only once were observed (results not shown). Thus, the slightly W. Kortlandt et al.: Glycated LDL catabolism in diabetes mellitus increased clearance in the vascular space of control LDL is not likely to be explained by some immune response. In human diabetic subjects with long-standing disease, antibodies to gly-LDL have been shown to be present reacting preferentiall~:~with glucitol!ysine [36] , obtained after re-:dUcfive iglycation ifi Vitr01~ We generated gly,LDL in the absence of reduCtive:iagent!i: ....... Brownlee et al. [37] Showed that gly=LDL binds to advanced glycosylated endproducts which are present at the endothelium of the arterial wall. Our rabbits were only diabetic for 2 weeks, so the presence of any increased advanced glycosylated endproducts of importance is unlikely.
Thus, increased catabolism of gly-LDL may be explained by increased macrophage activity. The scavenger receptor is expressed on macrophages and an increased activity might result in an increased clearance of LDL, preferentially gly-LDL. An increased activity of macrophages due to the alloxan treatment cannot be ruled out, although the time between treatment and LDL injection was at least 11 days. A greater activity of macrophages might be present as a result of an increased total concentration of glycated proteins. Macrophages have also been shown to react to in vivo glycated LDL with an increase in cholesterol ester production [38] .
In conclusion, we showed that LDL glycated in vitro under non-reductive conditions was catabolized at a slower rate than normal LDL in non-diabetic rabbits and that both lipoproteins were removed from the circulation at a faster rate after induction of diabetes mellitus by alloxan treatment reducing the difference in clearance between native LDL and glycated LDL. This would suggest that the non-receptor mediated removal of native and glycated LDL is enhanced by the diabetic state, leading to unexpectedly low gly-LDL levels and to a accelerated atherogenesis.
